Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

HyperCVAD regimen

View Patient Information
A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Hyper-CVAD regimen
hyperfractionated cyclophosphamide-vincristine-adriamycin-dexamethasone regimen
Abbreviation:HyperCVAD
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search